Cybin (CYBN) Competitors $7.45 +0.20 (+2.76%) Closing price 04:00 PM EasternExtended Trading$7.42 -0.03 (-0.34%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. GHRS, MRVI, TBPH, UPXI, MGTX, ABUS, KALV, KURA, BCAX, and TSHAShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include GH Research (GHRS), Maravai LifeSciences (MRVI), Theravance Biopharma (TBPH), Upexi (UPXI), MeiraGTx (MGTX), Arbutus Biopharma (ABUS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), Bicara Therapeutics (BCAX), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Its Competitors GH Research Maravai LifeSciences Theravance Biopharma Upexi MeiraGTx Arbutus Biopharma KalVista Pharmaceuticals Kura Oncology Bicara Therapeutics Taysha Gene Therapies Cybin (NYSE:CYBN) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership. Do analysts recommend CYBN or GHRS? Cybin presently has a consensus price target of $85.00, indicating a potential upside of 1,040.94%. GH Research has a consensus price target of $32.00, indicating a potential upside of 138.98%. Given Cybin's stronger consensus rating and higher possible upside, research analysts clearly believe Cybin is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25GH Research 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Do institutionals & insiders hold more shares of CYBN or GHRS? 17.9% of Cybin shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, CYBN or GHRS? GH Research is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.60-1.62GH ResearchN/AN/A-$38.96M-$0.74-18.09 Does the media refer more to CYBN or GHRS? In the previous week, Cybin had 17 more articles in the media than GH Research. MarketBeat recorded 18 mentions for Cybin and 1 mentions for GH Research. Cybin's average media sentiment score of 0.08 beat GH Research's score of 0.00 indicating that Cybin is being referred to more favorably in the media. Company Overall Sentiment Cybin Neutral GH Research Neutral Which has more volatility and risk, CYBN or GHRS? Cybin has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, GH Research has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Is CYBN or GHRS more profitable? GH Research's return on equity of -16.71% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% GH Research N/A -16.71%-16.06% SummaryCybin and GH Research tied by winning 7 of the 14 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$175.75M$853.50M$5.74B$21.17BDividend YieldN/A4.84%4.40%3.54%P/E Ratio-1.701.1530.4129.01Price / SalesN/A26.26428.9771.28Price / CashN/A19.5625.7818.23Price / Book0.696.779.704.72Net Income-$57.88M-$4.17M$3.27B$995.89M7 Day Performance13.05%3.84%3.94%2.56%1 Month Performance-6.76%2.35%3.81%2.81%1 Year PerformanceN/A12.14%31.26%11.07% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.3866 of 5 stars$7.45+2.8%$85.00+1,040.9%N/A$175.75MN/A-1.7050News CoverageGHRSGH Research1.4054 of 5 stars$12.67-0.9%$32.00+152.6%+14.8%$665.44MN/A-17.1210Upcoming EarningsMRVIMaravai LifeSciences4.0017 of 5 stars$2.57-1.5%$5.75+123.7%-73.1%$664.66M$259.18M-1.89610Positive NewsTBPHTheravance Biopharma1.8877 of 5 stars$13.61+3.5%$21.33+56.7%+70.6%$662.25M$77.21M56.71110News CoverageHigh Trading VolumeUPXIUpexi2.5098 of 5 stars$6.92-5.9%$15.50+124.0%+90.0%$656.81M$26M0.00130Positive NewsMGTXMeiraGTx4.5614 of 5 stars$7.97-2.4%$24.00+201.1%+81.8%$656.59M$33.28M-3.91300News CoveragePositive NewsABUSArbutus Biopharma2.685 of 5 stars$3.38+0.3%$5.50+62.7%-10.0%$645.07M$6.17M-11.6690Positive NewsKALVKalVista Pharmaceuticals3.945 of 5 stars$13.34+3.6%$26.29+97.0%+2.9%$643.41MN/A-3.62100News CoveragePositive NewsInsider TradeKURAKura Oncology3.9522 of 5 stars$7.48+1.9%$24.10+222.2%-62.1%$637.09M$53.88M-3.31130BCAXBicara Therapeutics1.5785 of 5 stars$11.47-1.5%$31.86+177.8%N/A$635.11MN/A-3.6232TSHATaysha Gene Therapies3.312 of 5 stars$2.93-0.3%$8.29+182.8%+32.7%$631.10M$8.33M-8.62180 Related Companies and Tools Related Companies GHRS Competitors MRVI Competitors TBPH Competitors UPXI Competitors MGTX Competitors ABUS Competitors KALV Competitors KURA Competitors BCAX Competitors TSHA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access